For years, medical professionals have touted exercise as a cornerstone of managing type 2 diabetes, but a new study suggests a potential complication for patients taking SGLT2 inhibitors. Research published in *Diabetes* indicates these commonly prescribed medications may lessen the cardiovascular and metabolic benefits typically achieved through physical activity. the findings highlight the complex interplay between pharmaceutical interventions and lifestyle choices, prompting a need for more personalized treatment strategies for the growing number of Americans-over 37 million-living with diabetes [[1]].
Diabetes Drug May Diminish Benefits of Exercise, Study Suggests
A new study indicates that a common medication used to manage type 2 diabetes could potentially reduce some of the health benefits typically gained from physical activity. The research, published recently, highlights a complex interaction between medication and lifestyle interventions, and underscores the importance of a holistic approach to health management.
Researchers found that individuals with type 2 diabetes taking sodium-glucose cotransporter-2 (SGLT2) inhibitors experienced less favorable cardiovascular and metabolic responses to exercise compared to those not on the medication. The study involved 17 participants with type 2 diabetes who were not taking any medications, and 26 participants already taking SGLT2 inhibitors. Participants underwent a series of exercise tests, including interval training, and researchers monitored their physiological responses.
“We observed that the positive effects of exercise on certain cardiovascular and metabolic markers were blunted in individuals taking SGLT2 inhibitors,” said one of the researchers involved in the study. Specifically, the medication appeared to interfere with the body’s ability to improve glucose metabolism and vascular function during exercise.
SGLT2 inhibitors work by preventing the kidneys from reabsorbing glucose, leading to increased glucose excretion in the urine. They are often prescribed to help lower blood sugar levels in people with type 2 diabetes. While these medications are effective in managing blood glucose, the new findings suggest a potential trade-off when it comes to the benefits of exercise.
The study participants exercised for six minutes at 85% of their maximum heart rate, followed by six minutes of recovery. Researchers assessed various parameters, including blood glucose levels, insulin sensitivity, and endothelial function – a measure of blood vessel health.
The findings suggest that individuals with type 2 diabetes taking SGLT2 inhibitors may need to adjust their exercise regimens or work with their healthcare providers to optimize their treatment plans. Further research is needed to fully understand the mechanisms behind this interaction and to determine the long-term implications for cardiovascular health. This research adds to the growing body of evidence demonstrating the intricate relationship between medications, lifestyle, and overall health outcomes.
Researchers emphasized that this study does not suggest people should stop taking their prescribed medications. Instead, it highlights the need for personalized treatment approaches that consider both pharmacological and non-pharmacological interventions, such as exercise.
The study was published in Diabetes here.
